Table 6 Single institution studies examining genotype-directed therapy
Study | Number of Subjects | Design | Rate of Actionable Alterations | Rate of Matched Therapy | Rate of Benefita |
|---|---|---|---|---|---|
Current study | 126 | Retrospective, single institution | 92% | 12% | 2% |
Vanderbilt [12] | 103 | Retrospective, single institution | 83% | 21% | 8% |
First MDACC [13] | 1144 | Prospective, phase 1 study | 40% | 18% | 5% |
UCSD [14] | 34 | Prospective, single institution, molecular tumor board | 94% | 35% | 21% |
Cornell [7] | 97 | Prospective, single institution | 94% | 5% | 2% |
Rutgers [15] | 92 | Prospective, single institution, molecular tumor board | 96% | 35% | NR |
Second MDACCb [16] | 339 | Prospective, single institution | 94% | 32% | NR |
University of Michigan [17] | 500 | NR | 72% | 5–11% | NR |